Multicenter, retrospective, and observational study of afatinib treatment in patients with non-small cell lung cancer harboring EGFR mutation who previously treated with EGFR-TKI.
Not Applicable
- Conditions
- non-small cell lung cancer harboring EGFR mutation
- Registration Number
- JPRN-UMIN000016916
- Lead Sponsor
- Central Japan Lung Study Group (CJLSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
1) Patients with pathologically proven non-small cell lung cancer
2) Patients with EGFR mutation (exon 19 deletion, exon 21 L858R, T790M, exon 20 insertion, and other minor mutations)
3) Second line or later therapy of afatinib previously treated with EGFR-TKI
Exclusion Criteria
1) Synchronous or metachronous (within 5 years) malignancies other than carcinoma in situ
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safty
- Secondary Outcome Measures
Name Time Method